Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Alvotech

Market Cap 131.73Cr 114.31Cr 105.37Cr 99Cr 184.48Cr 13TCr 188.32Cr 1.26TCr 486.66Cr 6.08TCr 494.51Cr 483.85Cr 21TCr P/E Ratio 2026 *
10.5x
P/E Ratio 2027 * 9.66x
Enterprise Value 241.63Cr 209.68Cr 193.28Cr 181.11Cr 338.38Cr 23TCr 345.43Cr 2.31TCr 892.67Cr 11TCr 907.07Cr 887.52Cr 39TCr EV / Sales 2026 *
3.66x
EV / Sales 2027 * 3.11x
Free-Float
36.85%
Yield 2026 *
-
Yield 2027 * -
1 day-5.35%
1 week-5.35%
Current month+5.36%
1 month-1.39%
3 months-5.09%
6 months-38.43%
Current year-30.99%
1 week 3.48
Extreme 3.48000000
4.59
1 month 2.94
Extreme 2.94
4.59
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.94
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
01/04Sell

Founder

3,18,000 0.0963%
01/04Free

Chief Executive Officer

1,17,271 0.0355%
01/04Buy

Founder

3,18,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
-5.35%-5.35%-64.99%-56.83% 131.73Cr
-1.40%+0.12%-14.73%-12.58% 4.3TCr
+3.50%-4.15%+265.85%+484.30% 3.17TCr
-0.61%-3.11%+14.00%-12.36% 3.02TCr
-1.27%-7.02%-0.82%+20.47% 2.89TCr
-0.66%-5.84%+7.59%+12.76% 2.39TCr
+2.01%+3.57%+57.15%+128.55% 1.36TCr
-1.65%-1.08%+7.92%+7.56% 1.3TCr
+2.77%-1.48% - - 1.34TCr
+0.68%-1.74%+103.98%+81.60% 1.22TCr
Average -0.20%-0.80%+41.77%+72.61% 2.11TCr
Weighted average by Cap. +0.11%-2.32%+52.81%+91.58%

Financials

2026 *2027 *
Net sales 66Cr 57Cr 53Cr 50Cr 93Cr 6.33TCr 94Cr 630.49Cr 244.1Cr 3.05TCr 248.04Cr 242.7Cr 11TCr 78Cr 68Cr 63Cr 59Cr 109.78Cr 7.51TCr 112.06Cr 747.99Cr 289.6Cr 3.62TCr 294.27Cr 287.93Cr 13TCr
Net income 16Cr 14Cr 13Cr 12Cr 23Cr 1.58TCr 24Cr 157.4Cr 61Cr 761.35Cr 62Cr 61Cr 2.65TCr 13Cr 12Cr 11Cr 10Cr 19Cr 1.28TCr 19Cr 127.92Cr 50Cr 618.73Cr 50Cr 49Cr 2.15TCr
Net Debt 109.9Cr 95Cr 88Cr 82Cr 153.91Cr 11TCr 157.11Cr 1.05TCr 406.01Cr 5.07TCr 412.56Cr 403.67Cr 18TCr 111.94Cr 97Cr 90Cr 84Cr 156.77Cr 11TCr 160.03Cr 1.07TCr 413.55Cr 5.17TCr 420.23Cr 411.17Cr 18TCr
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
11/26/11 4.220 $ +1.93% 8,96,655
10/26/10 4.140 $ -0.48% 6,17,621
09/26/09 4.160 $ -1.89% 14,31,206
08/26/08 4.240 $ +19.77% 22,65,909
05/26/05 3.540 $ -5.35% 6,94,104
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.220USD
Average target price
13.83USD
Spread / Average Target
+227.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!